Synergistic Antitumor Effect of Doxorubicin and Tacrolimus (FK506) on Hepatocellular Carcinoma Cell Lines

<table>PARP-1 cleaved, Beclin-1, LC3I, and LC3II protein expression analysis by western blotting in Huh7 and HepG2 cell lines after treatment with doxorubicin (0.85 <i>μ</i>M) and tacrolimus (0.052 <i>μ</i>M) and cotreatment (0.42 <i>μ</i>M dox plus 0.026 <i>μ</i>M tacr). GAPDH was used as loading control.</table>

The Scientific World Journal

fig3

Figure 3

Figure 3: Synergistic Antitumor Effect of Doxorubicin and Tacrolimus (FK506) on Hepatocellular Carcinoma Cell Lines 